Tubulin vinca-domain ligands can inhibit microtubule polymerization, causing cell death in mitosis, and their potential against multiple cancer types has been demonstrated. However, due to drug resistance and toxicities, development of novel vinca-domain ligands is still needed. In this study, we determined the high-resolution crystal structures of vinorelbine, YXD, and Phomopsin A in complex with tubulin at 2.5 Å. Additionally, we recapitulated all previously published high-resolution crystal structures of the vinca binding site to reveal critical residues and the molecular mechanism of vinca-domain ligands interacting with tubulin. Furthermore, we designed putatively novel triazolopyrimidine derivatives by introducing secondary amine groups to establish salt-bridge and H-bond interactions with Asp179 and Asn329 . Our studies provided the structural basis for designing novel tubulin vinca-domain ligands.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/1873-3468.14003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The high-resolution X-ray structure of vinca-domain inhibitors of microtubules provides a rational approach for drug design.
FEBS Lett
January 2021
Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Tubulin vinca-domain ligands can inhibit microtubule polymerization, causing cell death in mitosis, and their potential against multiple cancer types has been demonstrated. However, due to drug resistance and toxicities, development of novel vinca-domain ligands is still needed. In this study, we determined the high-resolution crystal structures of vinorelbine, YXD, and Phomopsin A in complex with tubulin at 2.
View Article and Find Full Text PDFStructural Investigation of Vinca Domain Tubulin Binders by Pharmacophore, Atom based QSAR, Docking and Molecular Dynamics Simulations.
Comb Chem High Throughput Screen
December 2018
Centre for Applied Chemistry, Central University of Gujarat, Gandhinagar 382030, Gujarat, India.
Article Synopsis
- The study focuses on the vinca domain of tubulin proteins as a target for microtubule-targeting drugs (MTD), highlighting the need for a better understanding of its binding mechanisms and structure-activity relationships to aid in drug development.
- Researchers created a pharmacophore model and conducted various simulations, including QSAR, molecular docking, and molecular dynamics, to identify potential inhibitors that effectively bind to the vinca domain.
- The developed model showed strong predictive capabilities with high statistical values, and the results indicate that the identified ligands bind stably within the target structure, paving the way for future drug discovery efforts.
Structural Insights into the Pharmacophore of Vinca Domain Inhibitors of Microtubules.
Mol Pharmacol
February 2016
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, China (Yu.W., Ya.W., Y.C., X.C., H.L., R.Z., J.Y.); Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Health Sciences Center, Louisville, Kentucky (F.W.B.); Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, China (Q.W.); and Pharmacology and Pharmaceutical Sciences School of Medicine, Tsinghua University and Collaborative Innovation Center for Biotherapy, Beijing, China (Y.Z.)
Antibody-drug conjugates (ADCs) have achieved great success in cancer therapy in recent years. Some peptidyl microtubule inhibitors consisting of natural and unnatural amino acids, such as monomethyl auristatin E (MMAE) and F (MMAF), are extremely cytotoxic and have been used as a payload in ADCs. However, their precise molecular interaction with tubulin and microtubules remains unclear.
View Article and Find Full Text PDFQSAR and 3D-QSAR models in the field of tubulin inhibitors as anticancer agents.
Curr Top Med Chem
August 2015
Department of Pharmaceutical and Pharmacological Science, University of Padova, via Marzolo 5, I- 35131 Padova, Italy.
Article Synopsis
- * Three primary binding sites on tubulin have been identified: the vinca, colchicine, and taxane domains.
- * The review discusses developed QSAR and 3D-QSAR models, focusing on research that explores how compounds bind to these target sites.
A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs.
Proc Natl Acad Sci U S A
September 2014
Department of Biology and Chemistry, Laboratory of Biomolecular Research, Paul Scherrer Institut, 5232 Villigen PSI, Switzerland;
Article Synopsis
- Recent advancements in antibody-drug conjugates (ADCs) for cancer treatment have sparked renewed research into microtubule-destabilizing agents.
- High-resolution crystal structures reveal how maytansine binds to β-tubulin, preventing the formation of microtubules by blocking specific interactions.
- This research outlines a unique mechanism of action for these drugs and lays the groundwork for developing new and more effective ADCs for cancer therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!